Juan Carlos Hernandez-Boluda at University of Valencia - Research Interests, Publications & Academic Profile

Juan Carlos Hernandez-Boluda

University of Valencia

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Nigerian students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

50%

Internal Medicine

40%

Hematology

70%

Cancer Therapy

30%

Comparative Oncology

20%

Targeted Therapy

20%

Liver Fibrosis

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

Article Link

Year:

2023

Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study

Article Link

Year:

2023

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Article Link

Year:

2023

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Article Link

Year:

2023

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping

Article Link

Year:

2023

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

Article Link

Year:

2023

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

Article Link

Year:

2022

CNL and aCML should be considered as single entity based on molecular profiles and outcomes.

Article Link

Year:

2022

An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

Article Link

Year:

2022

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

Article Link

Year:

2022

Collaborators10

Alexandros Rampotas

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM

Vikas Gupta

CANADA

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

SPAIN

Sergio Giralt

Chief Attending, Adult BMT Service

Memorial Sloan Kettering Cancer Center

UNITED STATES

Donal P. McLornan

UNITED KINGDOM

Francisca Ferrer‐Marín

SPAIN

Muhammad Bilal Abid

UNITED STATES

Jose Carlos Martinez Avila

Profesor Ayudante Doctor

Universidad Politécnica de Madrid

SPAIN

Nicolaus Kröger

GERMANY

Valentin Garcia

Profesor Asociado

Universidad de Alcalá

SPAIN

How do Nigerian students reach out?

Meet Kite AI